XML 31 R17.htm IDEA: XBRL DOCUMENT
v3.25.2

Note 7 - Intangible Assets | 12 Months Ended
--- | ---
Jun. 30, 2025
Notes to Financial Statements |
Intangible Assets Disclosure [Text Block] | Note 7 - Intangible Assets A summary of the Company’s intangible assets, all of which are definite-lived intangible assets, as of June 30, 2025, and June 30, 2024, is as follows:
|  | June 30, 2025 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Weighted- |
|  | Gross |  |  |  |  |  |  | Net |  |  | Average |
|  | Carrying |  |  | Accumulated |  |  | Carrying |  |  | Remaining |
|  | Amount |  |  | Amortization |  |  | Amount |  |  | Life (2) |
|  | (in thousands) |  |  | (in years) |
Product technology rights (1) |  | $ | 22,200 |  |  | $ | (5,592 | ) |  | $ | 16,608 |  |  |  | 12.7 |
Technology rights |  |  | 30,200 |  |  |  | (7,607 | ) |  |  | 22,593 |  |  |  | 12.7 |
Commercialization rights |  |  | 3,000 |  |  |  | — |  |  |  | 3,000 |  |  |  | N/A |
Total intangible assets |  | $ | 55,400 |  |  | $ | (13,199 | ) |  | $ | 42,201 |  |  |  | 12.7 |
(1) | In June 2025, the Company recorded an impairment to its product technology rights intangible asset of $8.3 million. Accordingly, $19.1 million of gross carrying amount and $10.8 million of related accumulated amortization have been removed from this table as of June 30, 2025.
(2) | The commercialization rights intangible asset will be considered placed in service upon the launch of EXXUA, which the Company currently anticipates launching in the fourth calendar quarter of 2025, and the initial estimated useful life of the commercialization rights is expected to be through September 2030.
|  | June 30, 2024 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Weighted- |
|  | Gross |  |  |  |  |  |  | Net |  |  | Average |
|  | Carrying |  |  | Accumulated |  |  | Carrying |  |  | Remaining |
|  | Amount |  |  | Amortization |  |  | Amount |  |  | Life |
|  | (in thousands) |  |  | (in years) |
Product technology rights |  | $ | 41,268 |  |  | $ | (13,184 | ) |  | $ | 28,084 |  |  |  | 10.7 |
Technology rights |  |  | 30,200 |  |  |  | (5,831 | ) |  |  | 24,369 |  |  |  | 13.8 |
Total intangible assets |  | $ | 71,468 |  |  | $ | (19,015 | ) |  | $ | 52,453 |  |  |  | 12.0 |
Gross carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. Renewal periods generally range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets from continuing operations included in the consolidated statements of operations for the years ended June 30, 2025, and 2024, are set forth in the below table:
​ |  | Year Ended |
​ |  | June 30, |
​ |  | 2025 |  |  | 2024 |
​ |  | (in thousands) |
Statement of operations classification: |  |  |  |  |  |  |  |
Cost of goods sold |  | $ | 1,306 |  |  | $ | 1,306 |
Operating expenses |  |  | 3,683 |  |  |  | 3,683 |
Total amortization of intangible assets expense |  | $ | 4,989 |  |  | $ | 4,989 |
The following table summarizes the estimated future amortization expense of intangible assets to be recognized over the next five years and periods thereafter:
|  | June 30, |
|  | (in thousands) |
2026 |  | $ | 3,489 |
2027 |  |  | 3,692 |
2028 |  |  | 3,692 |
2029 |  |  | 3,692 |
2030 |  |  | 3,692 |
Thereafter |  |  | 23,944 |
Total estimated future amortization expense |  | $ | 42,201 |
Product Technology Rights The product technology rights are related to the rights to production, supply and distribution agreements of various products. Karbinal The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August of 2033, with an optional initial 20-year extension. As a result of the Company’s shifted focus of its commercial efforts on EXXUA and its ADHD Portfolio the Company recorded a full impairment of these intangible assets in June 2025, resulting in impairment expense of $2.7 million being recognized. Please refer to Note 12 - Fair Value Measurements for further discussion on the fair value measurement of intangible assets. Poly-Vi-Flor and Tri-Vi-Flor The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. As a result of the Company’s shifted focus of its commercial efforts on EXXUA and its ADHD Portfolio the Company recorded a full impairment of these intangible assets in June 2025, resulting in impairment expense of $5.6 million being recognized. Please refer to Note 12 - Fair Value Measurements for further discussion on the fair value measurement of intangible assets. ADHD Portfolio The Company has developed product technology rights related to the production and sale of Adzenys and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated remaining economic life of these proprietary product technology rights is 12.6 years. Technology Rights TRRP Proprietary Technology The Company has time release resin particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well. The estimated remaining economic life of these proprietary technology rights is 12.6 years. Commercialization Rights As part of the Commercialization Agreement for the exclusive commercialization rights of EXXUA in the United States, the Company capitalizes to the carrying value of intangible assets any contingent payments made that are considered a part of the Commercialization Agreement’s total consideration and which are not within the scope of derivative guidance once the contingencies related to these payments are resolved. Once the commercialization rights are considered placed in service on the launch date of EXXUA, the Company will amortize the commercialization rights on a straight-line basis over the estimated life of the asset and the Company will adjust the carrying value of the commercialization rights on a cumulative catch-up basis as if the additional capitalized amount had been capitalized on the same date that the intangible asset was placed in service. As of June 30, 2025, the commercialization rights were not placed in service and as a result, no amortization expense was recorded for this intangible asset. The Company currently anticipates launching EXXUA in the fourth calendar quarter of 2025, and the initial estimated useful life of the commercialization rights is expected to be through September 2030.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration